Theravance Biopharma, Inc. stock is up 9% since 30 days ago. The next earnings date is Feb 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 9 December’s closed higher than November.
Theravance Biopharma, Inc. discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD) Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor.